TD Waterhouse Canada Inc. Has $19.68 Million Stock Holdings in Danaher Co. (NYSE:DHR)

TD Waterhouse Canada Inc. lowered its position in Danaher Co. (NYSE:DHR) by 20.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 85,710 shares of the conglomerate’s stock after selling 21,713 shares during the period. TD Waterhouse Canada Inc.’s holdings in Danaher were worth $19,680,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Danaher by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock valued at $13,715,641,000 after buying an additional 315,912 shares in the last quarter. Geode Capital Management LLC lifted its position in Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock valued at $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank bought a new stake in Danaher during the 4th quarter worth approximately $2,130,740,000. Bank of New York Mellon Corp raised its stake in shares of Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after purchasing an additional 441,012 shares during the last quarter. Finally, Capital World Investors lifted its holdings in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.0 %

Shares of Danaher stock opened at $184.96 on Tuesday. The company has a 50 day simple moving average of $201.64 and a two-hundred day simple moving average of $226.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a market cap of $132.19 billion, a PE ratio of 35.03, a PEG ratio of 2.66 and a beta of 0.86. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm posted $2.09 EPS. Analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. lowered their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company cut their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Citigroup reiterated a “buy” rating on shares of Danaher in a report on Monday, April 7th. Finally, The Goldman Sachs Group upgraded Danaher from a “neutral” rating to a “buy” rating and set a $260.00 target price on the stock in a research note on Friday, March 21st. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $274.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.